Joseph Treat is an Oncology physician affiliated with Fox Chase Cancer Center. OpenAlex indexes 140 publications with 3,681 citations (h-index 30); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 191112434
Telephone
215-728-6900Registry record last updated 9 Apr 2018.
Clinical trials
- Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Sponsor: Fox Chase Cancer Center
- S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Sponsor: SWOG Cancer Research Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year202523 payments$18,377openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year20244 payments$18,574openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.7%Kinase inhibitor51.6%Tagrisso100%Part D≥14 patientsOther antineoplastic agents6%Krazati100%Part D<11 patientsMetabolism & gastrointestinal
20.9%Serotonin-3 Receptor Antagonist12.6%Ondansetron Hcl100%Part D≥19 patientsCorticosteroid8.2%Prednisone100%Part D≥14 patientsNervous system
13.7%Opioid Agonist7.1%Oxycodone Hcl100%Part D<11 patientsPhenothiazine6.6%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1997–1999 per NIH RePORTER. The latest:
- CLINICAL TRIALS OF AD.RSVTK IN PATIENTS WITH MALIGNANT MESOTHELIOMA
University of Pennsylvania
FY1999P01CA066726 - CLINICAL TRIALS OF AD.RSVTK IN PATIENTS WITH MALIGNANT MESOTHELIOMA
University of Pennsylvania
FY1998P01CA066726 - GENE THERAPY OF MALIGNANT MESOTHELIOMA USING E1 DELETED ADENOVIRUS
University of Pennsylvania
FY1997M01RR000040
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy
Journal of Cancer Research and Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Elizabeth Plimack, MD
Fox Chase Cancer Center
Robert Uzzo, MD02041967
Fox Chase Cancer Center
John Ridge, MD
Fox Chase Cancer Center
Eric Horwitz, MD
Fox Chase Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”